- Home
- UFCS vs GERN Comparison
UFCS vs GERN Comparison
Compare UFCS & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UFCS | GERN |
|---|---|---|
| Founded | 1946 | 1990 |
| Country | United States | United States |
| Employees | N/A | 229 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 936.4M | 1.1B |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | UFCS | GERN |
|---|---|---|
| Price | $48.23 | $1.42 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $40.50 | $2.17 |
| AVG Volume (30 Days) | 85.8K | ★ 14.8M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.01% | N/A |
| EPS Growth | ★ 87.45 | N/A |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $1,386,412,000.00 | N/A |
| Revenue This Year | $11.80 | $26.91 |
| Revenue Next Year | $8.77 | $43.75 |
| P/E Ratio | $40.72 | ★ N/A |
| Revenue Growth | ★ 10.62 | N/A |
| 52 Week Low | $25.81 | $1.04 |
| 52 Week High | $47.27 | $2.01 |
Technical Indicators
Market Signals| Indicator | UFCS | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 78.74 | 37.29 |
| Support Level | $36.27 | $1.24 |
| Resistance Level | N/A | $1.49 |
| Average True Range (ATR) | 1.39 | 0.09 |
| MACD | 0.72 | -0.01 |
| Stochastic Oscillator | 93.05 | 1.45 |
Price Performance
Historical ComparisonAbout UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.